The identification of novel tumour-associated antigens is urgently needed to improve the efficacy of immunotherapy for multiple myeloma (MM). In this study, we identified a membrane protein MMSA-1 (multiple myeloma special antigen-1) that was specifically expressed in MM and exhibited significantly positive correlation with MM. We then identified HLA-A*0201-restricted MMSA-1 epitopes and tested their cytotoxic T lymphocyte (CTL) response. The MMSA-1 epitope SLSLLTIYV vaccine was shown to induce an obvious CTL response in vitro. To improve the immunotherapy, we constructed a multi-epitope peptide vaccine by combining epitopes derived from MMSA-1 and Dickkopf-1 (DKK1). The effector T cells induced by multi-epitope peptide vaccine-loaded dendritic cells lysed U266 cells more effectively than MMSA-1/DKK1 single-epitope vaccine. In myeloma-bearing severe combined immunodeficient mice, the multi-epitope vaccine improved the survival rate significantly compared with single-epitope vaccine. Consistently, multi-epitope vaccine decreased the tumour volume greatly and alleviated bone destruction. The frequencies of CD4 + and CD8 + T cells was significantly increased in mouse blood induced by the multiepitope vaccine, indicating that it inhibits myeloma growth by changing T cell subsets and alleviating immune paralysis. This study identified a novel peptide from MMSA-1 and the multi-epitope vaccine will be used to establish appropriate individualized therapy for MM.
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Keywords: MMSA-1, immunotherapy, multiple myeloma, DKK1, epitope.
Multiple myeloma (MM) is a haematological malignancy characterized by accumulation of monoclonal globulins in bone marrow, causing osteolytic bone destruction and haematopoiesis failure. The morbidity and mortality of MM has increased worldwide in recent years (Mehta et al, 2014; Walz et al, 2015) . Some strategies, such as the immunomodulatory drugs thalidomide and lenalidomide, and the proteasome inhibitor bortezomib, as well as high-dose therapy/autologous stem cell transplantation, appear to have improved the outcome and resulted in better disease control and survival with improved quality of life (Cherry et al, 2013) . However, this disease continues to be incurable, with fatal outcomes for most patients in the advanced stages. Increasing research attention and emphasis have been paid on immunotherapy that targets minimal residual disease (MRD) using the host immunological system to eliminate the remaining malignant cells in the bone marrow (BM), in the hope of curing the disease (Danylesko et al, 2012; Mahindra et al, 2012) . To date, many studies have shown results with great potential. One of the most promising immunotherapeutic approaches is the use of monoclonal antibodies (mAbs), such as that targeting CD38 (de Weers et al, 2011) . Furthermore, mAbs specific for CS1, CD40, CD74, CD70, HM1Á24, interleukin (IL) 6 and b2-microglobulin (b2-MG) have also been studied (Benson et al, 2011; Korthals et al, 2012; Sherbenou et al, 2015) . Immunotherapy might be an appropriate strategy to control residual disease, as well as providing an alternative treatment modality to conventional chemotherapy for MM patients. Peptide vaccines derived from target proteins represent another promising strategy to provoke an immune reaction that kills MM cells (Walz et al, 2015) . For example, peptides derived from XBP1 and MAGE-A3 showed potent cytotoxic activities towards MM cell lines and primary MM cells (Bae et al, 2011; Moreno-Bost et al, 2011) . Peptide vaccines have attracted considerable attention for their potential to destroy cancerous cells (Perez et al, 2010) . The development of an effective immunotherapy depends on discovering more powerful tumour antigens through advances in molecular biology technology (Zhou et al, 2010; Zhang et al, 2012b) . Peptidebased immunotherapy is a promising strategy to generate desirable immune responses that will change the survival outlook for MM rapidly (Zhou et al, 2010) .
The MMSA-1 (multiple myeloma special antigen) gene was first discovered by our group via a serological analysis of a recombinant cDNA expression library (Zhou et al, 2006a, b) . The sequence was submitted to GenBank with Accession No. AY952881 and later modified to AY952881.8 after the full-length mRNA sequence was obtained using 5 0 rapid amplification of cDNA ends. Sequence analysis showed that it is likely a mutant of the ZDHHC9 gene, which is associated highly with colorectal cancer (Mansilla et al, 2007) . The MMSA-1 protein is principally distributed on cell membranes, although there is a small quantity in the cytoplasm (Meng et al, 2012) . In a small number of MM patients, the mRNA and protein levels of MMSA-1 are upregulated significantly compared with healthy donors and was observed to be higher in relapsed/refractory patients than in newly diagnosed patients (Meng et al, 2016) . More interestingly, MMSA-1 is expressed specifically in MM patients and is associated with poor prognosis (Meng et al, 2016) , suggesting that it could be a potential candidate antigen for MM immunotherapy. In this study, we enlarged the patient numbers to examine the expression of MMSA-1, study its biological function and explore its potential as a unique surface antigen for immunotherapy of MM. Dickkopf-1 (DKK1) plays pivotal roles in bone health. It is a key regulator of myeloma bone disease and disrupts osteoblast differentiation and function via the Wnt signal pathway (Zhou et al, 2013) . DKK1 is highly expressed in the tumour cells of almost all myeloma patients (Tian et al, 2003) . Active vaccination with a DKK1 peptide as tumourassociated antigen in MM induces protective and therapeutic anti-tumour immunity (Qian et al, 2007 (Qian et al, , 2012 . This suggested that DKK1 is an important antigen for MM immunotherapy. Combined vaccines show promise for clinical use. Multi-epitope peptide vaccines are being hailed as the next generation in cancer immunotherapy (Bae et al, 2012; Nezafat et al, 2014) , with the benefits of safety and cost-effective production, and a more lethal effect on tumours (Cho & Celis, 2012) . Therefore, multi-epitope peptide vaccines are predicted to be potent agents in the treatment of MM (Zhou et al, 2010) . In this study, we constructed a multi-epitope vaccine comprising epitopes from MMSA-1 and DKK1, and investigated the elicitation of protective immunity against MM in vitro and in vivo. The combined vaccine will be used to establish appropriate individualized immunotherapy for MM and opens up a new vista for cancer treatment.
Materials and methods

Patients and ethical approval and informed consent
The study was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Committees of Medical School of Xi'an Jiaotong University. All human participants gave written informed consent.
The study included 94 MM patients registered with the Medical School of Xi'an Jiaotong University. Primary myeloma cells were isolated from BM aspirates collected from MM patients using density gradient centrifugation and antihuman CD138 antibody-coated magnetic microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany) (Qian et al, 2005) . Plasma cells isolated from patients with leukaemia (n = 40), anaemia (n = 18) and pulmonary infection (n = 10), as well as from healthy donors (n = 16) were used as controls and preserved in liquid nitrogen until use. CD8 + T cells were isolated from peripheral blood mononuclear cells (PBMCs) of healthy donors using anti-human CD8 mAb coated magnetic microbeads (Life technology, Carlsbad, CA, USA).
Cell culture
The human myeloma cell lines (HMCLs) HMy2, RPMI8226 and U266 were purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA). The human acute monocytic leukaemia cell lines THP-1 and U937 were used as negative controls (NC). K562 and A549 were purchased from the China Infrastructure of Cell Line Resources (Beijing, China). K562 was used as natural killer (NK) cell-sensitive target and A549 was used as an NC. USA). The primer sequences and thermocycler protocol are shown in supplemental Table 1 .
Western blotting analysis
In brief, after sample cells were prepared, total protein was extracted and subjected to sodium dodecyl sulphate-polyacrylamide gel electrophoresis analysis. After transferring the protein onto polyvinylidene fluoride membrane and subsequent blocking, the membranes were immunoblotted with rabbit anti-human MMSA-1 primary antibody (1:500, Abcam, Cambridge, MA, USA) overnight at 4°C, followed by incubation with horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG secondary antibody (Signalway antibody, Baltimore, MD, USA) for 2 h at room temperature. This was followed by detection of the HRP signal by enhanced chemiluminescence (Pierce Biotechnology, Rockford, IL, USA).
Cell assay
The cell proliferation, apoptosis, cell cycle and cell migration abilities were analysed to further explore the biological role of MMSA-1 in myeloma cells, using previously described protocols (Yang et al, 2014) .
Epitope prediction and peptide synthesis
Bioinformatic methods were used to predict and identify MMSA-1/HLA-A*0201 restricted CTL epitopes, as previously reported, to determine the potential of MMSA-1 as a target for myeloma immunotherapy (Tanu et al, 2014; Trajanoski et al, 2015) . In brief, a computational supermotif algorithm (SYF-PEITHI), combined with a quantitative motif algorithm (BIMAS), was used for the prediction and BLAST analysis was performed to confirm their specificity to MMSA-1 (Liu et al, 2012; Zhang et al, 2012a) . According to the two calculation scores, the top four candidate epitopes (P1, P2, P3, P4) were verified and synthesized (GL Biochem, Shanghai, China) and the purity of synthetic peptides were all >95%. A peptide from the influenza virus matrix protein 58 GILGFVFTL 64 ) was used as a positive control (Qian et al, 2007) (Acierno et al, 2003) . All the peptides were dissolved in phosphate-buffered saline (PBS) and stored at À20°C until use.
Peptide-T2 cell binding assay
The HLA-A*0201-specific binding affinities of the candidate epitopes were examined in a T2 cell binding assay, using previously reported protocols (Qian et al, 2007) , as shown in Data S1.
Measurement of T lymphocytes cytotoxicity in vitro
Generation of dendritic cells. Monocyte-derived mature dendritic cells (DCs) were generated from PBMCs obtained from HLA-A*0201-positive (HLA-A*0201 + ) healthy donors using standard protocols (Tkachenko et al, 2005; Qian et al, 2009; Bae et al, 2012) , as shown in Data S1. After DCs maturation, they were collected and the expressions of surface markers (CD80, CD83, CD86, CD1a, CD11c and HLA-DR) were examined by flow cytometry using previously reported protocols (Bae et al, 2015) .
Generation of peptide-specific T cells in vitro. CD8 + T cells were selected from the non-adherent population of HLA-A*0201 PBMCs by anti-human CD8 mAb-coated magneticactivated cell sorting techniques. Peptide-specific T cells were generated from PBMCs obtained from HLA-A*0201 positive (HLA-A*0201 + ) blood donors by repeated stimulation of autologous CD8 + T cells with peptide-loaded mature DCs.
Briefly, DCs and CD8 + T cells (ratio 10:1) were co-cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS), IL7 (5 ng/ml), IL12 (5 ng/ml) and IL2 (5 ng/ ml) containing 100 nmol/l peptides for 1 week. The cultures were fed every 3 days with fresh medium containing the cytokines and peptides. After three cycles of in vitro stimulation and selection, peptide-specific T cells were established and subjected to functional tests.
CTL cytotoxicity test. The standard lactate dehydrogenase (LDH)-release assay was performed to measure the cytotoxic activity of the peptide-specific T cells against target cells (U266 cells), according to previously described protocols (Lin et al, 2012) . In this experiment, both negative controls (secreted LDH in the normal state) and positive controls (released LDH in the lysate) were used to validate the results. Enzyme-linked immunosorbent assay (ELISA) was used to measure the levels of secreted IL2 and interferon (IFN)-c in the supernatants, using commercially available kits (R&D Systems, Minneapolis, MN, USA).
Immune reconstitution and tumour cell transplantation in SCID mice
Female severe combined immunodeficient (SCID) mice (aged 4-6 weeks, n = 50) were purchased from Shanghai Experimental Animal Centre of Chinese Academy of Sciences (Shanghai, China) and kept in a pathogen-free animal facility in laminar airflow cabinets, with a 12 h light/12 h dark schedule. The animals were fed with an autoclaved rodent diet ad libitum. All procedures followed the institutional and national guidelines for the care and use of laboratory animals. Natural killer cell activity in the mice was blocked by intraperitoneal injection of anti-asialo GM1 (20 ll) and irradiation (3 Gy, X line of ionization chamber M-150WE). The immune system of SCID mice was reconstructed by intraperitoneal injection of 0Á5 ml human peripheral blood lymphocytes (4 9 10 7 /ml) from a HLA-A*0201 single donor within each experiment. After 24 h, mice received 
Immunization
After tumour cell transplantation, tumour growth was monitored every 3 days. Starting when the tumour volume reached 100-120 mm 3 , the mice in five groups (n = 10, each) received subcutaneous dorsal immunization with 0Á5 ml of peptide vaccines containing 50 lg of the peptide emulsified in 0Á5 ml of incomplete Freund's adjuvant (IFA) at one-week intervals for 3 weeks. Within 2 weeks after the third immunization, tumour volumes in each group were examined and tumour inhibition rates were calculated. Fourteen days after the third immunization, serum samples were also collected for determination of erythrocyte sedimentation rate (ESR) and immunoglobulin G (IgG) levels. ELISA was used to detect serum b2 microglobulin (b2-MG), k light chains, IFN-c and IL4 using standard protocols.
Measurement of peripheral blood T cell subsets and T lymphocyte cytotoxicity in vivo
After immunotherapy, mice were selected randomly from each group for sacrifice. Peripheral blood samples were collected and the T cell subsets and Treg cells were detected by flow cytometry with PE Cy5-CD3/FITC-CD4/PE-CD8 (eBioscience, San Diego, CA, USA) using standard protocols. The results were analysed using BD FACSDiva Software (Beckton Dickinson, San Jose, CA, USA). Splenocytes were also isolated from the mice and re-suspended and cultured in six-well plates in RPMI 1640 medium (Hyclone, Logan, UT, USA) supplemented with 5% FBS and IL2 (20 iu/ml) for 5 days as effector cells. U266 target cells were co-incubated with effector cells at different effector:target (E:T) ratios in RPMI 1640 medium containing 5% FBS for 4 h. The LDH-release assay was then performed to measure the cytotoxic activity of the splenocytes.
Micro-computed tomography analysis
The femur bones of the sacrificed mice were isolated and fixed with formalin before evaluation of femur bone changes by micro-computed tomography (micro-CT), as described previously (Shuai et al, 2015) .
Statistical analysis
All statistical analyses were performed using the SPSS statistical software version 13Á0 (SPSS Inc., Chicago, IL, USA) or GraphPad Prism 5Á0 (GraphPad Prism Software, San Diego, CA, USA). Differences among the experimental groups were subjected to ANOVA. P-values of less than 0Á05 were considered to indicate statistical significance. Unless otherwise indicated, data represent the means AE standard deviation (SD) of at least three repeated experiments.
Results
MMSA-1 is highly expressed in myeloma cell lines and is associated with myeloma bone disease-related cytokines in MM patients Examination of the expression levels of MMSA-1 mRNA and protein are shown in Fig 1. In the three myeloma cell lines (HMy2, RPMI8226 and U266) and primary myeloma cells isolated from 94 patients, the level of MMSA-1 mRNA was markedly higher than that in patients with leukaemia, anaemia, pulmonary infection and healthy donors (P < 0Á05, Fig 1A) . Similarly, the MMSA-1 protein was detected in all three myeloma cell lines and in 47 of 60 myeloma patients, whereas in other patients, the abundance of MMSA-1 was low or absent ( Fig 1B) .
To examine the physiological relevance, myeloma bone disease (MBD)-related cytokines were assayed in the serum of MM patients and control samples (Data S1). MM patients showed significantly higher levels of osteolytic cytokines (IL6 and DKK1) (P < 0Á001, Figure S1A and B) and markedly lower level of osteogenic cytokines (OPG) (P < 0Á001, Figure S1C ). Moreover, a correlation analysis showed that the levels of osteolytic cytokines were positively correlated with the level of MMSA-1 mRNA expression, whereas the level of osteogenic cytokine was negatively correlated with the level of MMSA-1 mRNA expression in the patients (P < 0Á001, Fig 1C, D 
and E).
Silencing MMSA-1 resulted in inhibited proliferation, accelerated apoptosis, cell cycle arrest at S/G2 phase and inhibited cellular migration
To further examine the biological function of MMSA-1, ten siRNAs targeting MMSA-1 were synthesized (the sequences are listed in Table S1 ); si-5 showed the highest interference rate, and resulted in a 60% decrease in the level of MMSA-1 mRNA, as determined by RT-PCR ( Figure S2 ). Therefore si-5 was used in subsequent assays for proliferation, apoptosis, cell cycle and migration of cells.
The proliferation of U266 cells was inhibited after transfection of si-5 (si-RNA group) compared with both the Cell group (blank control group without treatment) and NC group (negative control group transfected with control siRNA, which has no effect on any genes) (P < 0Á05, Fig 2A) . Cell apoptosis was detected by flow cytometry. Forty-eight hours after transfection, the late apoptosis rate in the si-5-transfected cells (si-RNA group) was twice that of the other two groups (P < 0Á001, Fig 2B) . Cell cycle analysis showed that the S phase was significantly prolonged in the si-RNA group compared with the other two groups (P < 0Á05 vs. Cell group; P < 0Á01 vs. NC group) and that the G2 phase was shortened (P < 0Á05 vs. Cell group; P < 0Á05 vs. NC group), resulting in cell cycle arrest in the S/G2 phase (Fig 2C) . The migration ability of the cells was examined using a transwell chamber assay. At 48 h after silencing of MMSA-1, the number of cells in the si-RNA group that migrated to the lower chamber was significantly lower than that in the Cell and NC groups (P < 0Á05, Fig 2D) .
Taken together, these findings suggested that silencing of MMSA-1 resulted in a marked change in the biological behaviour of myeloma cells: myeloma cell proliferation was markedly inhibited, cell apoptosis was accelerated, the cell cycle was arrested and the cellular migration ability was inhibited. ) that could potentially bind to HLA-A*0201 molecules. Their binding affinities and stabilities were measured using a peptide-T2 binding assay. The results showed that the optimal peptide binding concentration was 100 nmol/l (P < 0Á05, Fig 3A) , and the best time for peptide incubation with T2 cells was 24 h (P < 0Á05, Fig 3B) .
MMSA-1 as a candidate antigen for myeloma immunotherapy
Subsequently, the cytotoxic activities of the four peptides were tested. P2 peptide-pulsed T2 cells presented the strongest cell-killing effect compared with the other peptides and the Flu-matrix control peptide on the U266 cell line (P < 0Á05; Fig 3C) . Therefore, the P2 peptide was selected for further analysis.
Cytotoxicity analysis showed that MMSA-1 specific T cells could effectively lyse MMSA- and (E) show correlations of MMSA-1 transcript levels and IL6, DKK1 and OPG levels, respectively. **P < 0Á01; ***P < 0Á001.
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normal blood cells (Fig 3D) . These results indicated that the MMSA-1 peptide was presented in the context of HLA-A*0201 molecules by myeloma cells, the cytotoxicity was antigen-specific and it is safe for use in normal blood cells. To assess cytokine secretion, ELISA was used to detect the levels of IL2, IL12 and IFN-c secreted by the effector cells. The secreted levels of IL2, IL12 and IFN-c were correlated positively with cytotoxicity against U266 cells (HLA-A*0201 + ) (P < 0Á05; Fig 3E) . However, IL2, IL12 and IFN-c levels against RPMI8226 cells (HLA-A*0201 À ) were very low (Fig 3F) , which were consistent with the cytotoxic activity assay.
Construction of a novel multi-epitope vaccine comprising MMSA-1 and DKK1 epitopes induced a strong CTL response in vitro Combined vaccine approaches are used to decrease the tumour burden and modulate regulatory pathways and have the potential to be clinically useful. MMSA-1 exhibited a significantly positive correlation with DKK1 peptide-specific CTLs in MM patients ( Fig 1D) ; therefore, we constructed a novel peptide comprising MMSA-1 and DKK1 epitopes to evaluate the combined efficacy for the treatment of MM.
We selected an MMSA-1-targeted HLA-A*0201-restricted epitope (P2: 190 SLSLLTIYV 198 ) and a DKK1-targeted HLA-A*0201-restricted epitope ( 20 ALGGHPLLGV 29 ) to construct the MMSA-1 + DKK1 multi-epitope peptide (SLSLLTIYV-SGSG-ALGGHPLLGV). A repeated sequence containing two serine and two glycine amino acid residues (SGSG) was used to link the MMSA-1 and DKK1 epitopes.
To determine the anti-myeloma effect of MMSA-1 and DKK1 HLA-A*0201 CTL peptide vaccines on MM cells, we firstly confirmed the expression of HLA-A*0201 on the U226 and THP-1 cells, and that the RPMI8226 and U937 cells were negative ( Figure S3 ). We then cultured mature DCs from human PBMCs and the identity of these cells was confirmed on the basis of surface marker expression ( Figure S4 ). Autologous CD8 + T cells and peptide-loaded mature DCs were co-cultured to produce effector T cells. Evaluation of Cell migration ability changes after transfection by siRNAs. *P < 0Á05, **P < 0Á01, ***P < 0Á001. Cell, blank control group without treatment; NC, negative control group transfected with control siRNA.
CTL cytotoxicity showed that effector T cells induced by the HLA-A*0201-restricted MMSA-1 + DKK1 multi-epitope peptide-loaded DCs effectively lysed MMSA-1 + /DKK1 + /HLA-A*0201 + U266 cells (86Á57%), while those induced by DCs loaded with the individual MMSA-1 or DKK1 epitopes were less effective (60Á13% and 73Á04% lysis, respectively) ELISA was used to determine cytokine release (IFN-c and IL2) by these cells in co-culture and further confirm that the MMSA-1 + DKK1 multi-epitope vaccine induced effective CTL responses. The concentrations of IL2 and IFN-c were significantly higher in the MMSA-1 + DKK1 multi-epitope group than in the MMSA-1 and DKK1 single-epitope groups (Fig 4E-F) , providing further evidence of the superior immunogenicity of the MMSA-1 + DKK1 combined multiepitope vaccine.
The MMSA-1 + DKK1 combined multi-epitope vaccine improved the survival rate in a SCID MM model
To investigate the effects of the MMSA-1 + DKK1 combined vaccine in vivo, we constructed a mouse model of MM by subcutaneous transplantation of human U266 MM cells into immune reconstructed SCID mice. Four mice per group were used for survival analysis. By day 60, over half of the mice in the experimental groups had died, so the survival curves stop at day 60. The MMSA-1 + DKK1 combined multi-epitope vaccine greatly improved the mean survival time of tumourbearing mice with a mean survival time of 60Á00 AE 1Á00 days, compared with 47Á5 AE 4Á57 days and 51Á0 AE 6Á24 days in mice treated with PBS (Blank group, P < 0Á01) and positive control peptide (Flu-matrix group, P < 0Á05). We did not find statistical differences between MMSA-1 + DKK1 combined multi-epitope vaccine, MMSA-1 and DKK1 single-epitope vaccines, possibly because of the limited observation time (P > 0Á05, Fig 5A) .
Furthermore, we found that the ESR (Brigden, 1999 ) and b2-MG levels (Durie et al, 1990) , which are associated with poor prognosis of MM patients, were also decreased in the MMSA-1 + DKK1 combined multi-epitope group (Fig 5B) . These results were consistent with the survival time of the mice observed in the MM model.
Similarly, the MMSA-1 + DKK1 combined multi-epitope vaccine significantly inhibited tumour growth (Fig 5C) , with inhibition rates reaching 81Á80% (Table I) . Additionally, lower levels of the k-light chain, which is a diagnostic index of MM, were observed in the MMSA-1 + DKK1 combined multi-epitope group (Fig 5D) , indicating a reduced tumour load in the MM model.
The combined multi-epitope vaccine induced CD4
+ and CD8 + T cell responses and cytokine secretion
We investigated the mechanism underlying the effects of the vaccines by flow cytometric analysis of T cell subsets isolated from mouse blood. There were significantly higher numbers of CD3 + CD4 + T cells (Fig 6A) and CD3 + CD8 + T cells (Fig 6B) in the MMSA-1 + DKK1 combined multi-epitope group compared with the other groups. Although the numbers of CD3 + CD25 + Treg cells were not significantly different between the groups, the tendency was lower in the MMSA-1 + DKK1 combined multi-epitope group than in the other groups (Fig 6C) . This indicated that the multi-epitope combined vaccine enhances the specific CTL responses and releases immune tolerance caused by regulatory T cells. Mouse splenocytes from the MMSA-1 + DKK1 combined multi-epitope group mediated a stronger cytotoxic effect on U266 cells in vitro compared with those derived from the single-epitope groups (Fig 6D) . Similarly, higher levels of IFN-c were secreted into the serum of the MMSA-1 + DKK1 combined multi-epitope group compared with the single-epitope groups (Fig 6E) , while IL4 levels (Th2-type cytokine) decreased (Fig 6F) . This observation was consistent with the results of the LDH-release assay, suggesting that the MMSA-1 + DKK1 combined vaccine mainly induced cellular immunity. Thus, our findings confirmed that the MMSA-1 + DKK1 combined vaccine induces stronger CTL responses than those induced by the single-epitope vaccines alone.
The combined vaccine significantly alleviated the bone destruction in MM mice Importantly, micro-CT coronal and sagittal scans showed that MMSA-1 + DKK1 combined vaccine significantly Tumour inhibition rate (%)
*Tumour volumes were calculated using the following formula: Inhibition rate (%) = (tumour volume in control group -tumour volume in experimental group)/tumour volume in control group 9 100%. †Means compared with MMSA-1 + DKK1 multi-epitope vaccine group.
A Novel Vaccine Elicits Potent Anti Myeloma Effect
ª 2017 John Wiley & Sons Ltd alleviated the bone destruction caused by MM cells (Fig 7) . Moreover, a series of impact factors of the bone, such as object volume, structure linear density, structure separation, fragmentation index, number of pores, volume of pores, percent porosity and bone mineral density were also improved (Table II) .
Discussion
With the original discovery of the expression of human cancer cell-specific surface antigens through serological techniques, immunotherapy for cancer has become one of the fastest growing and most successful strategies to treat patients with haematological malignanciesand solid tumours (Rettig & Old, 1989) . Many targets that are overexpressed, mutated or selectively expressed on tumour cells have been used to develop immunotherapeutic agents towards different cancers. One of the key challenges is the identification of cancer cellspecific antigens that are suitable for immunotherapy (Scott et al, 2012) . Furthermore, because myeloma patients show the phenomenon of immune escape, we need to find more potent antigens to improve the anti-myeloma effect (Klippel et al, 2014) . The MMSA-1 gene was identified by screening an expression library created from the HMy2 cell line (Zhou et al, 2006a) and MMSA-1 mRNA expression was relatively highly and specifically expressed in a small number of MM patients (Meng et al, 2016) , therefore we predicted that MMSA-1 plays a role in multiple myeloma. In this study, we proved that MMSA-1 is relatively specifically expressed in both myeloma cell lines and primary myeloma cells from a large cohort of MM patients. The level of MMSA-1 mRNA correlated closely with the levels of osteolytic cytokines and osteogenic cytokines in MM patients. MMSA-1 is involved in the migration of myeloma cells and might be responsible for accelerating cell cycle progression by inhibiting cell apoptosis in the genesis of myeloma cells, indicating the functional significance of MMSA-1 and making it a desirable target for MM immunotherapy.
In an attempt to generate the MMSA-1-specific immunotherapy towards MM, we generated MMSA-1 peptide-specific CTLs from PBMCs of healthy donors that showed a strong cytolytic activity against MMSA-1 peptidepulsed T2 cells and MMSA- not autologous mature DCs that were not pulsed with MMSA-1 peptides, confirming that MMSA-1 peptides are naturally presented in the context of HLA-A*0201 molecules and that the cytotoxicity was antigen-specific, thus, the peptides are safe for use against normal blood cells. Interestingly, we observed some cytotoxic activity on RPMI8226 cells, which have mis-matched HLA-A*0201 molecules. However, the release of IL2, IL12 and IFN-c was not as high as the release of LDH. The possible reason may be because RPMI8226 cells are sensitive and vulnerable to changes in culture conditions, which caused cell death but no cytotoxic cytokine release. In future studies, we will attempt to identify other HLA-A*0201 ligands and by + CD8 + T cells (B) and CD3 + CD25 + Treg cells (C) were isolated from mouse blood and assayed by flow cytometry. Mouse splenocytes were isolated and co-cultured with U266 cells; peptide-specific lysis of U266 cells was determined by a lactate dehydrogenase (LDH) release assay (D). Serum levels of (E) IFN-c and (F) IL4 were determined by enzyme-linked immunosorbent assay (ELISA). *P < 0Á05. connecting multiple epitopes, will overcome antigen loss and immune escape. DKK1 is highly expressed by the tumour cells of almost all myeloma patients (Tian et al, 2003) . Qian et al (2007) identified and synthesized HLA-A*0201-restricted DKK1 peptides and confirmed their immunogenicity by in vivo immunization of HLA-A*0201 transgenic mice. Furthermore, their study showed that the active immunity induced by the DKK1 vaccine (ALGGHPLLGV) not only protected mice from developing myeloma, but also showed a therapeutic effect against established disease. Mechanistic studies revealed that the DKK1 vaccine elicited strong DKK1-and tumourspecific CD4 + and CD8 + T cell responses in vaccinated mice (Qian et al, 2012) . In our recent review, we also summarized the opportunities and challenges of DKK1 as a key regulator of myeloma bone disease (MBD) for therapeutic intervention (Zhou et al, 2013) . MMSA-1 and DKK1 mRNA levels were positively correlated in MM patients (Fig 1D) , and DKK1 is considered to play a key role in the development of MBD by interrupting the Wnt-regulated differentiation of osteoblasts directly, resulting in significant morbidity and impaired quality of life (Rammensee et al, 1999; Lemaire et al, 2010; Xu et al, 2011) . DKK1 is part of a classic Wnt signaling pathway that directly depletes b-catenin. Therefore, it would be reasonable to assume that MMSA-1 might also be a key member of the Wnt signaling pathway and play an important role in the genesis and progression of MBD (He et al, 2013; Jin et al, 2015) . This remains to be studied in the future. *Because of the limitation of the mouse number, in this part only two mice were detected in every group, and the result were shown as an average and we did not perform a statistical analysis. To optimize immunotherapy methods, the identification of novel shared myeloma antigens is required urgently to stimulate efficient anti-myeloma CTL responses in the majority of treated patients. Combining CTL epitopes will contribute to a synergistic effect for immunotherapy of MM. In this study, we linked an MMSA-1 epitope ( 190 SLSLLTIYV 198 ) and DKK1 epitope ( 20 ALGGHPLLGV 29 ) to construct a multi-epitope vaccine (SLSLLTIYV-SGSG-ALGGHPLLGV), which induced strong CTL responses in vivo and in vitro, and elicited protective immunity against MM in vivo.
Novel HLA-A*0201 (HLA-A2)-restricted CTL epitopes from a B cell-specific molecule, HLA-DOb (DOB), as a potential target for MM have been identified (Kang et al, 2013) . It highlights the potential therapeutic application of vaccination with a cocktail of HLA-A2-specific peptides that induce CTLs with a broad spectrum of immune responses against MM antigens. Interestingly, in our study, the MMSA-1 and DKK1 CTL epitopes were designed according to their capacity to bind to HLA-A*0201 molecules, which is the main HLA-I antigen subtype in the Chinese population. The MMSA-1 and/or DKK1 peptides bound to the HLA-A*0201 positive U266 and THP-1 cell lines, but not to the negative RPMI8226 and U937 cell lines, thus confirming the major histocompatibility comlpex restriction of the immune responses and anti-tumour effects of the peptide vaccines. These data suggested that the anti-myeloma effect was mediated by the responses to the two antigens in a HLA-restricted manner. The results of the in vivo studies were consistent with the in vitro results, and demonstrated that the multiepitope combined vaccine induced stronger CTL responses than those induced by the single-epitope vaccine alone, and that the MMSA-1 + DKK1 combined vaccine greatly improved the survival time in tumour-bearing mice and alleviated bone destruction.
In conclusion, we confirmed MMSA-1 as a myeloma associated antigen and that MMSA-1 might be a good candidate antigen for MM immunotherapy. The constructed MMSA-1 + DKK1 combined vaccine induced stronger CTL responses in vitro and improved the survival time and alleviated bone destruction in vivo by enhancing cellular immunity and releasing immune tolerance. Our study suggested the potential of the MMSA-1 + DKK1 combined vaccine for immunotherapy of MM, opening up a new vista for cancer treatment.
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